Rhythm Pharmaceuticals (RYTM) Retained Earnings (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Retained Earnings data on file, last reported at $444000.0 in Q1 2026.

• On a quarterly basis, Retained Earnings rose 100.04% year-over-year to $444000.0 in Q1 2026; TTM through Mar 2026 was $444000.0, a 100.04% increase from a year earlier, with the FY2025 full-year figure at $1.5 billion, up 3824907.69% from the prior year.
• Retained Earnings for Q1 2026 stood at $444000.0, down from $1.5 billion in the prior quarter.
• Over the last five years, Retained Earnings for RYTM reached as high as $1.5 billion in Q4 2025 and fell as low as -$1.3 billion in Q3 2025.
• Historically, Retained Earnings has averaged $191.5 million across 5 years, with a median of $134000.0 in 2023.
• On a YoY basis, Retained Earnings climbed as much as 3824907.69% in 2025 and fell as far as 662883.43% in 2025.
• Year by year, Retained Earnings stood at -$92000.0 in 2022, then jumped by 245.65% to $134000.0 in 2023, then tumbled by 129.1% to -$39000.0 in 2024, then soared by 3824907.69% to $1.5 billion in 2025, then plunged by 99.97% to $444000.0 in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $444000.0 in Q1 2026, $1.5 billion in Q4 2025, and -$1.3 billion in Q3 2025.